Brokerages Expect Aurora Cannabis Inc. (NYSE:ACB) to Post -$0.16 Earnings Per Share

Wall Street analysts predict that Aurora Cannabis Inc. (NYSE:ACBGet Rating) will report ($0.16) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for Aurora Cannabis’ earnings, with estimates ranging from ($0.21) to ($0.13). Aurora Cannabis reported earnings per share of ($0.24) in the same quarter last year, which would indicate a positive year-over-year growth rate of 33.3%. The company is expected to report its next quarterly earnings results on Monday, January 1st.

According to Zacks, analysts expect that Aurora Cannabis will report full year earnings of ($0.66) per share for the current fiscal year, with EPS estimates ranging from ($0.74) to ($0.60). For the next financial year, analysts anticipate that the firm will post earnings of ($0.46) per share, with EPS estimates ranging from ($0.62) to ($0.26). Zacks’ EPS averages are a mean average based on a survey of research firms that cover Aurora Cannabis.

Aurora Cannabis (NYSE:ACBGet Rating) last issued its quarterly earnings results on Thursday, February 10th. The company reported ($0.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.25). The business had revenue of $48.07 million for the quarter, compared to analyst estimates of $45.87 million. Aurora Cannabis had a negative net margin of 167.83% and a negative return on equity of 11.52%.

A number of research firms recently issued reports on ACB. CIBC lowered their target price on Aurora Cannabis from C$9.25 to C$6.50 in a report on Thursday, February 3rd. Zacks Investment Research raised Aurora Cannabis from a “sell” rating to a “hold” rating in a report on Monday, January 31st. Finally, Cantor Fitzgerald lowered their target price on Aurora Cannabis from C$10.75 to C$7.60 in a report on Friday, February 11th. Three investment analysts have rated the stock with a sell rating and eight have given a hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $6.98.

Shares of ACB opened at $3.54 on Wednesday. The stock’s fifty day moving average is $3.80 and its 200-day moving average is $5.37. Aurora Cannabis has a one year low of $2.89 and a one year high of $10.64. The company has a debt-to-equity ratio of 0.19, a current ratio of 4.92 and a quick ratio of 3.70.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Geode Capital Management LLC lifted its holdings in Aurora Cannabis by 0.6% in the 3rd quarter. Geode Capital Management LLC now owns 294,825 shares of the company’s stock worth $2,039,000 after purchasing an additional 1,660 shares during the last quarter. Credit Suisse AG increased its position in Aurora Cannabis by 0.7% in the 3rd quarter. Credit Suisse AG now owns 237,960 shares of the company’s stock worth $1,646,000 after buying an additional 1,722 shares during the period. Advisor Group Holdings Inc. increased its position in Aurora Cannabis by 2.9% in the 3rd quarter. Advisor Group Holdings Inc. now owns 60,912 shares of the company’s stock worth $423,000 after buying an additional 1,732 shares during the period. Aurora Private Wealth Inc. increased its position in Aurora Cannabis by 19.2% in the 3rd quarter. Aurora Private Wealth Inc. now owns 11,918 shares of the company’s stock worth $82,000 after buying an additional 1,917 shares during the period. Finally, Private Advisor Group LLC increased its position in Aurora Cannabis by 10.4% in the 3rd quarter. Private Advisor Group LLC now owns 22,029 shares of the company’s stock worth $152,000 after buying an additional 2,079 shares during the period. Hedge funds and other institutional investors own 17.61% of the company’s stock.

Aurora Cannabis Company Profile (Get Rating)

Aurora Cannabis Inc produces, distributes, and sells cannabis and cannabis derivative products in Canada and internationally. It also engages in facility engineering and design, cannabis breeding, research, production, derivatives, product development, wholesale, and retail distribution activities. The company produces various strains of dried cannabis, cannabis oil and capsules, and topical kits for medical patients.

Recommended Stories

Get a free copy of the Zacks research report on Aurora Cannabis (ACB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aurora Cannabis (NYSE:ACB)

Receive News & Ratings for Aurora Cannabis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurora Cannabis and related companies with MarketBeat.com's FREE daily email newsletter.